Skip to main content

27.02.2025 | letter to the editors

Response to comment on “Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: A retrospective single center experience”

verfasst von: Catharina Müller, MD, Thomas Bachleitner-Hofmann, MD, Stefan Riss, MD

Erschienen in: Wiener klinische Wochenschrift

Einloggen, um Zugang zu erhalten

Excerpt

We thank Safwan et al. for the comments on our publication “Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: A retrospective single center experience” [1]. In the following we want to clarify the points raised by Safwan et al. …
Literatur
2.
Zurück zum Zitat Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg. 2022;407(7):3057–67.CrossRefPubMed Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg. 2022;407(7):3057–67.CrossRefPubMed
3.
Zurück zum Zitat Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140–8.CrossRefPubMed Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140–8.CrossRefPubMed
4.
Zurück zum Zitat Yaşar S, Yılmaz F, Utkan G, Algın E, Bayram D, Tamam S, et al. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol. 2024;31(9):6228–36.CrossRefPubMedPubMedCentral Yaşar S, Yılmaz F, Utkan G, Algın E, Bayram D, Tamam S, et al. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol. 2024;31(9):6228–36.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh I, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36–59.CrossRefPubMed Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh I, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36–59.CrossRefPubMed
6.
Zurück zum Zitat Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70.CrossRefPubMed Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70.CrossRefPubMed
7.
Zurück zum Zitat Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2905–13.CrossRefPubMed Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2905–13.CrossRefPubMed
8.
Zurück zum Zitat Steffens D, Koh C, Ansari N, Solomon MJ, Brown K, McBride K, et al. Quality of life after cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy: early results from a prospective cohort study of 115 patients. Ann Surg Oncol. 2020;27(10):3986–94.CrossRefPubMed Steffens D, Koh C, Ansari N, Solomon MJ, Brown K, McBride K, et al. Quality of life after cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy: early results from a prospective cohort study of 115 patients. Ann Surg Oncol. 2020;27(10):3986–94.CrossRefPubMed
9.
Zurück zum Zitat Stearns AT, Malcomson L, Punnett G, Abudeeb H, Aziz O, Selvasekar CR, et al. Long-term quality of life after cytoreductive surgery and heated Intraperitoneal chemotherapy for pseudomyxoma peritonei: a prospective longitudinal study. Ann Surg Oncol. 2018;25(4):965–73.CrossRefPubMed Stearns AT, Malcomson L, Punnett G, Abudeeb H, Aziz O, Selvasekar CR, et al. Long-term quality of life after cytoreductive surgery and heated Intraperitoneal chemotherapy for pseudomyxoma peritonei: a prospective longitudinal study. Ann Surg Oncol. 2018;25(4):965–73.CrossRefPubMed
Metadaten
Titel
Response to comment on “Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: A retrospective single center experience”
verfasst von
Catharina Müller, MD
Thomas Bachleitner-Hofmann, MD
Stefan Riss, MD
Publikationsdatum
27.02.2025
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-025-02507-9